Analyst Expectations for Inozyme Pharma's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Inozyme Pharma (NASDAQ:INZY) with an average price target of $18.6, implying an upside from the current price of $4.85. This represents a 2.11% decrease from the previous average price target of $19.00.
September 08, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bullish analyst ratings and a higher price target suggest a potential upside for Inozyme Pharma.
Analysts have provided bullish ratings for Inozyme Pharma, indicating a positive outlook for the company. The average price target of $18.6 is significantly higher than the current price of $4.85, suggesting a potential upside. However, this represents a 2.11% decrease from the previous average price target, indicating a slight decrease in optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100